Atea Pharmaceuticals expects cash runway into mid-2028
AVIR•Atea Pharmaceuticals expects its $191.2 million in cash and investments as of Sept. 30, 2026, plus a $65 million initial draw from its Hercules Capital credit facility, to fund operations into mid-2028. It targets a mid-2027 US marketing application for BEM/RZR, whose peak annual US net sales could exceed $700 million.
1. Cash runway and plans
Atea Pharmaceuticals said existing cash and its initial $65 million draw on a credit facility with Hercules Capital are expected to fund operations into mid-2028. Cash and investments totaled $191.2 million on Sept. 30, 2026; the facility provides up to $200 million.
2. BEM/RZR outlook
Atea targets a US marketing application for BEM/RZR in mid-2027. Peak annual US net sales could exceed $700 million, and pricing is expected to align with existing branded direct-acting antiviral regimens. Additional funding and a successful launch could bring Atea toward profitability.
